Second-line antibody-drug conjugates for the treatment of metastatic human papillomavirus-independent gastric-type adenocarcinoma of cervix: The Singapore experience

Abstract

Human papillomavirus (HPV)-independent gastric-type adenocarcinoma (GAS) is a rare, aggressive, chemoresistant histological subtype of cervical cancer which occurs more commonly in patients of Asian descent. Patients with GAS tend to have poorer overall outcomes compared to HPV-associated adenocarcinomas of the cervix. The antibody-drug conjugates (ADCs) tisotumab vedotin-tftv (TV) and trastuzumab deruxtecan (T-DXd) are approved for use in previously treated metastatic cervical cancer, the latter in HER2-expressing tumors. There is paucity of data regarding the efficacy and safety of TV and T-DXd in the management of metastatic GAS. We report outcomes of four patients with metastatic GAS who were treated with these ADCs in the second-line setting in Singapore.